海外の治験の状況「1」での検索結果
259件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- This is an open-label, multi-center, dose escalation Phase 1/2a study to establish the recommended dose for Phase 2 (RP2D) from Phase 1a and Phase 1b, as well as evaluating the preliminary efficacy of the RP2D in expansion cohorts (Phase 2a) in patients with liver related cancers.
- hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), or, metastatic liver disease MedDRA version: 20.0 Level: PT Classification code 10073071 Term: Hepatocellular carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10073077 Term: Intrahepatic cholangiocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10027479 Term: Metastatic liver carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, Korea, Republic of, United Kingdom, United States
- 2018-08-09
Authorised
- Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN)
- Immunoglobulin A Nephropathy (IgAN) MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
- Australia, Belgium, Croatia, Czech Republic, Estonia, France, Germany, Hong Kong, Hungary, Italy, Korea, Republic of, Lithuania, Malaysia, New Zealand, Poland, Portugal, Spain, Turkey, United Kingdom, United States
- 2018-07-30
Authorised
- Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN)
- Immunoglobulin A Nephropathy (IgAN) MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
- Australia, Belgium, Croatia, Czech Republic, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom, United States
- 2018-07-17
Authorised
- A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.
- Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belarus, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2018-03-02
Authorised
- A study to determine if A4250 is safe and can be used to treat children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2.
- Progressive Familial Intrahepatic Cholestasis Types 1 and 2 MedDRA version: 20.0 Level: PT Classification code 10076033 Term: Progressive familial intrahepatic cholestasis System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Saudi Arabia, Spain, Sweden, Turkey, United Kingdom, United States
- 2018-02-19
Authorised
- Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)
- Diabetic Foot Ulcer;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Czech Republic, Hungary, India, Poland, United States
- 2019-01-08
Authorised
- A Clinical Trial for Newly Diagnosed High Risk ER+/HER2– (Estrogen Receptor Positive/ Human Epidermal growth factor receptor Negative) Breast Cancer
- High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer MedDRA version: 20.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Colombia, France, Germany, Hungary, Ireland, Israel, Japan, Korea, Republic of, New Zealand, Poland, Portugal, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom, United States
- 2018-10-19
Authorised
- A comparison of brentuximab vedotin and CHP with standard-of-care CHOP in the treatment of patients with CD30-positive mature T-cell lymphomas
- CD30-positive mature T-cell lymphomas MedDRA version: 19.0 Level: HLGT Classification code 10025321 Term: Lymphomas non-Hodgkin's T-cell System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Romania, Spain, Taiwan, United Kingdom, United States
- 2012-11-07
Authorised
- International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia
- Philadelphia positive Acute Lumphoblastic Leukemia MedDRA version: 20.0 Level: PT Classification code 10034877 Term: Philadelphia chromosome positive System Organ Class: 10022891 - Investigations MedDRA version: 20.0 Level: LLT Classification code 10000844 Term: Acute lymphoblastic leukaemia System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Canada, Chile, Czech Republic, Denmark, European Union, Finland, France, Germany, Hong Kong, Israel, Italy, Netherlands, Poland, Sweden, Switzerland, United Kingdom, United States
- 2017-10-30
Authorised
- Chymase inhibitor BAY 1142524 in patients with type II diabetes and a clinical diagnosis of diabetic kidney disease
- type II diabetic mellitus (T2DM) patients with a clinical diagnosis of diabetic kidney disease (CKD);Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Bulgaria, Denmark, Finland, Israel, Italy, Spain, Sweden
- 2017-10-05
